Boltz, a public-benefit AI research company building tools for biomolecular modeling and design, is now tracked in Turing Tree. Its platform supports scientists working on molecular structures, binding affinity, and protein and small-molecule design.
Its co-founder and CEO, Gabriele Corso, helped create Boltz-1, an open model for predicting how biological molecules interact. His earlier research includes DiffDock, a method for estimating how a potential drug may fit a target protein.